Revised labeling for prescription and over-the-counter proton pump inhibitors (PPIs) will warn that these stomach acid–reducing medications could increase patients’ risk of hip, wrist, and spine fractures, US health authorities announced. The FDA’s decision to add new precautionary information to PPI labeling is based on data from 7 epidemiological studies published since 2006. Six of the 7 showed a relationship between PPI use and an increased risk of fractures. Most of the patients in the studies were aged 50 years or older; the increased risk of fracture was seen primarily in this group.